Elizabeth Rozek Biography and Net Worth

General Counsel of Sagimet Biosciences

Elizabeth Rozek joined Sagimet in April 2023, bringing more than 20 years of legal and corporate experience. From December 2020 to December 2022, Ms. Rozek served as general counsel and chief compliance officer of pediatric behavioral digital health company Cognoa, Inc. From January 2010 to December 2020, she served in roles of increasing responsibility at Basilea Pharmaceutica International Ltd., a Swiss-listed biopharmaceutical company with global operations developing and commercializing anti-infective and oncology products, where she was ultimately named general counsel and corporate secretary. From 2001 to 2006, Ms. Rozek served as a US Department of Justice civil prosecutor on the team that successfully prosecuted the tobacco industry under RICO. As general counsel and chief compliance officer of Sagimet, Ms. Rozek serves as an internal strategic business partner and leads the legal organization, including corporate governance, IP and compliance functions. Ms. Rozek received a BA from Brown University, an MA from University of California San Diego and a JD from the University of California Berkeley.

What is Elizabeth Rozek's net worth?: The estimated net worth of Elizabeth Rozek is at least $1.17 million as of July 21st, 2025. Rozek owns 183,726 shares of Sagimet Biosciences stock worth more than $1,166,660 as of December 5th. This net worth estimate does not reflect any other assets that Rozek may own. Learn More about Elizabeth Rozek's net worth.
How old is Elizabeth Rozek?: Rozek is currently 52 years old. There are 4 older executives and no younger executives at Sagimet Biosciences. The oldest executive at Sagimet Biosciences is Dr. George W. Kemble Ph.D., Executive Chairman of the Board, who is 62 years old. Learn More on Elizabeth Rozek's age.
How do I contact Elizabeth Rozek?: The corporate mailing address for Rozek and other Sagimet Biosciences executives is , , . Sagimet Biosciences can also be reached via phone at 650-561-8600 and via email at [email protected]. Learn More on Elizabeth Rozek's contact information.
Has Elizabeth Rozek been buying or selling shares of Sagimet Biosciences?: Elizabeth Rozek has not been actively trading shares of Sagimet Biosciences within the last three months. Most recently, Elizabeth Rozek sold 10,780 shares of the business's stock in a transaction on Monday, July 21st. The shares were sold at an average price of $9.13, for a transaction totalling $98,421.40. Following the completion of the sale, the general counsel now directly owns 183,726 shares of the company's stock, valued at $1,677,418.38. Learn More on Elizabeth Rozek's trading history.
Who are Sagimet Biosciences' active insiders?: Sagimet Biosciences' insider roster includes David Happel (Chief Executive Officer & Director), George Kemble (Chairman), Eduardo Martins (Chief Medical Officer), Elizabeth Rozek (General Counsel), and Beth Seidenberg (Director). Learn More on Sagimet Biosciences' active insiders.
Are insiders buying or selling shares of Sagimet Biosciences?: During the last twelve months, insiders at the sold shares 4 times. They sold a total of 122,223 shares worth more than $1,061,625.27. The most recent insider tranaction occured on November, 20th when Chairman George Kemble sold 37,688 shares worth more than $289,820.72. Insiders at Sagimet Biosciences own 14.7% of the company. Learn More about insider trades at Sagimet Biosciences.
Information on this page was last updated on 11/20/2025.

Elizabeth Rozek Insider Trading History at Sagimet Biosciences

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
7/21/2025	Sell	10,780	$9.13	$98,421.40	183,726
7/19/2024	Sell	10,914	$3.10	$33,833.40	160,506

Elizabeth Rozek Buying and Selling Activity at Sagimet Biosciences

Sagimet Biosciences Company Overview

Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States. The company's lead drug candidate is Denifanstat, a once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction associated steatohepatitis. It also develops TVB-3567, a FASN inhibitor for the treatment of acne; and other oncology programs. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.

Today's Range

Now: $6.35

$6.19

$6.55

50 Day Range

MA: $7.56

$6.09

$9.14

2 Week Range

Now: $6.35

$1.73

$11.41

Volume

809,338 shs

Average Volume

478,418 shs

Market Capitalization

$206.50 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

3.32

Elizabeth Rozek Biography and Net Worth

What is Elizabeth Rozek's net worth?

How old is Elizabeth Rozek?

How do I contact Elizabeth Rozek?

Has Elizabeth Rozek been buying or selling shares of Sagimet Biosciences?

Who are Sagimet Biosciences' active insiders?

Are insiders buying or selling shares of Sagimet Biosciences?